此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Individualized Genotype-guided Antiplatelet Therapy in Patients With Acute Coronary Syndrome (IGNITION)

2026年11月9日 更新者:Medisch Spectrum Twente

Rationale Patients diagnosed with acute coronary syndrome (ACS), a sudden medical emergency where blood flow to the heart is blocked, require dual antiplatelet therapy (DAPT) for 12 months to prevent dangerous blood clots to form. This typically includes the combination of aspirin and a form of P2Y12 inhibitor, a specific type of medicine that stops platelet cells to clot. Irrespective of the treatment strategy (i.e., invasive through angioplasty or conservative with medication only), the somewhat more potent P2Y12 inhibitor ticagrelor is advised over clopidogrel. Yet, clopidogrel can be considered for patients with a higher bleeding risk, as it is associated with fewer bleeding events.

Although ischemic complications (problems that happen when the heart doesn't get enough blood and oxygen) usually appear in the first 30 days after ACS diagnosis, the bleeding risks remains high through the entire period of DAPT. A de-escalation strategy (switch from ticagrelor to clopidogrel after 30 days) could theoretically reduce the number of bleeding events, without increasing the number of ischemic events. However, in 30% of the (white) European patients, there is a small change (mutation) in their genetic material. They are carriers of at least one so called CYP2C19 loss-of-function (LOF) allele, which results in a poor or intermediate processing of clopidogrel in to its active form.

Despite knowledge of these loss of function mutations, current treatment guidelines for ACS do not provide specific recommendations on individualized, genotype-based treatment (i.e. using the unique genetic code to choose the medicine that works best) with P2Y12 inhibitors. In addition, previous conducted trials on a de-escalation strategy have not led to strong recommendations, as they were too small and cautious to give definite answers.

Objective The goal of this clinical trial is to investigate whether individualized genotype-guided treatment with DAPT after ACS diagnosis is just as safe and effective as standard clinical practice.

Participants will receive:

  1. Standard treatment at the discretion of the cardiologist, or
  2. Genotype-guided treatment (based on the presence of a LOF allele)

Participants included in the genotype-guided group who do not carry a LOF allele will be classified as normal processors of clopidogrel, and will de-escalate after 30 days from standard therapy to clopidogrel. If patients are proven carriers of one of the LOF alleles, de-escalation will not take place and treatment will continue as previously started.

Participants will be followed for 18 months after ACS diagnosis to collect medical data and to complete questionnaires.

研究概览

详细说明

Rationale Patients diagnosed with acute coronary syndrome (ACS) require dual antiplatelet therapy (DAPT) for 12 months. This typically includes aspirin and a P2Y12 inhibitor. Irrespective of the treatment strategy (i.e., invasive or conservative), the somewhat more potent P2Y12 inhibitor ticagrelor is advised over clopidogrel. Yet, clopidogrel can be considered for patients with a higher bleeding risk, as it is associated with fewer bleeding events.

Although ischemic complications usually appear in the first 30 days after ACS diagnosis, the bleeding risks remains high through the entire period of DAPT. A de-escalation strategy (switch from ticagrelor to clopidogrel after 30 days) could theoretically reduce the number of bleeding events, without increasing the number of ischemic events. Yet, in 30% of the (white) European patients are carriers of at least one so called CYP2C19 loss-of-function (LOF) allele, which results in a poor or intermediate metabolization of clopidogrel.

Despite knowledge of these loss of function mutations, current ACS guidelines do not provide specific recommendations on individualized, genotype-based treatment with P2Y12 inhibitors. In addition, previous conducted trials on a de-escalation strategy have not led to strong recommendations, as the conucted trials were underpowered due to sample size calculations based on ischemic endpoints, and the exclusion of ACS patients with high-risk features.

Objective

This randomized clinical trial aims to investigate whether individualized genotype-guided DAPT is non-inferior at 18 months follow-up to standard clinical practice of DAPT in all-comer patients with ACS with regard to:

  • the primary endpoint of Ischemic Endpoint, a composite of cardiovascular death, myocardial infarction, or ischemic stroke, and
  • the co-primary endpoint of Net Adverse Cardiovascular Events (NACE), a composite of major bleeding, cardiovascular death, myocardial infarction, or any stroke.

Trial design This is a randomized, investigator-initiated, multicentre trial with 1:1 randomization of all-comer ACS patients for genotype-guided antiplatelet therapy, stratified for the presence of diabetes mellitus, sex and PCI.

Trial population All patients of 18 years or older with ACS, irrespective of the treatment strategy. If patients did not undergo a coronary angiography, there must be a history of coronary artery disease, proven myocardial defect by cardiac imaging that matches with previous MI, proven myocardial ischemia, or a known coronary obstruction ≥30% as previously visualized.

Interventions

If no major events (defined by NACE) occur during the first 30 days, patients will be randomly assigned (1:1) to:

  1. Standard treatment at the discretion of the cardiologist, or
  2. Genotype-guided treatment (based on CYP2C19 loss of function alleles) Patients included in the genotype-guided group who do not carry a LOF allele will be classified as normal or ultrafast metabolizers, and will de-escalate after 30 days from standard therapy (with ticagrelor or prasugrel) to clopidogrel. If patients are proven carriers of one of the LOF alleles, de-escalation will not take place and treatment will continue as previously started. If the test results are inconclusive, de-escalation will be carried out.

Ethical considerations As both treatment strategies (i.e. aspirin plus clopidogrel or ticagrelor or prasugrel) are commonly used in treatment of ACS and considered standard care in Europe according to the ESC guidelines, no risks will be attached to treatment with any of the P2Y12 inhibitors. Patients who receive an individualized treatment strategy will possibly benefit from this, due to lower risk of bleeding complications.

研究类型

介入性

注册 (估计的)

3120

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Eline Ploumen, MD, PhD
  • 电话号码:+31(0)53 487 2105
  • 邮箱:e.ploumen@mst.nl

学习地点

    • Overijssel
      • Almelo、Overijssel、荷兰、7609 PP
        • Ziekenhuis Groep Twente
        • 接触:
          • Joost Kruik, MD
          • 电话号码:+31(0)88 708 33 00
          • 邮箱:j.kruik@zgt.nl
      • Enschede、Overijssel、荷兰、7512 KZ
        • Medisch Spectrum Twente
        • 接触:
          • Eline Ploumen, MD, PhD
          • 电话号码:+31(0)53 487 2105
          • 邮箱:e.ploumen@mst.nl

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Patients of 18 years and older, who are capable of providing informed consent and were diag-nosed with an acute coronary syndrome

  • Patients with a coronary angiography showing obstructive coronary artery disease at time of di-agnosis (or up to 30 days thereafter)

  • Patients in whom no coronary angiography is performed during the index hospitalization or the first 30 days after the ACS, need to have at least one of the following:

    • known history of coronary artery disease (i.e., a previous MI, PCI, or coronary artery bypass grafting (CABG)),
    • proven myocardial defect by cardiac imaging that matches with previous MI,
    • proven myocardial ischemia, or
    • known coronary artery atherosclerosis as previously visualized.

Exclusion Criteria:

  • Known intolerance to or absolute contraindication for clopidogrel, ticagrelor, prasugrel or acetyl-salicylic acid.
  • Use of oral anticoagulant therapy.
  • Contra-indication for standard treatment with ticagrelor.
  • Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure (thoracoscopic or lap-aroscopic) within the past 6 months prior to randomization or any major surgical procedure planned 6 months after randomization.
  • Participation in another randomized cardiovascular device trial or randomized pharmacological trial related to antithrombotic and/or anticoagulant therapy before reaching the primary end-point.
  • Known pregnancy, adherence to scheduled follow-up is unlikely, or life expectancy is assumed to be less than 18 months.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Standard therapy

Dual antiplatelet therapy described at the cardiologist's discretion

Patients randomized for the standard therapy arm will receive dual antiplatelet therapy at the descretion of the cardiologist

实验性的:Genotype based therapy

Dual antiplatelet therapy based on CYP2C19 genotype. In case of normal or ultrafast metabolizer, patient will receive Clopidogrel 30-days after acute coronary syndrome. In case of proven carrier of the loss-of-function allele, patient will continue with ticagrelor.

All patients with ACS can be enrolled. Randomization will take place at time of ACS diagnosis. For the first 30 days after the index event, patients will be treated with DAPT as prescribed by the cardiologist. Patients who experience a major event (any death, spontaneous MI, definite stent thrombosis, any stroke, and major bleeding) during the first 30 days will be excluded from the main analysis. For these patients, DAPT treatment will remain unchanged.

Included patients will be randomly assigned (1:1) to:

  1. Standard treatment at the discretion of the cardiologist
  2. Genotype-guided treatment In the patients randomized to the intervention arm genotyping will be performed and patients who do not carry a LOF allele will be classified as normal or ultrafast metabolizers. In these patients, de-escalation of P2Y12 inhibitor from standard therapy to clopidogrel will be performed around 30 days. If patients are proven carriers of one of the LOF alleles, de-escalation will not take place.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Ischemic endpoint
大体时间:At 18 months follow-up

Composition of cardiovascular death, myocardial infarction, definite stent thrombosis and ischemic stroke

At 18 months follow-up
Net Adverse Cardiovascular Events
大体时间:At 18 months follow-up

Composition of cardiovascular death, major bleeding, myocardial infarction, definite or probable stent thrombosis, and any stroke

At 18 months follow-up

次要结果测量

结果测量
措施说明
大体时间
Adverse events
大体时间:At 18 months follow-up

Death, Myocardial infarction, repeat revascularization, stroke, stent thrombosis, and bleeding

At 18 months follow-up
Patient reported chest pain
大体时间:At 12- and 18-months follow-up

Severity of chest pain by the Canadian Cardiovascular Society Angina Grade score classified into four classes (I to IV) based on the amount of exertion that triggers the symptoms. The higher the class, the lower the exercise tolerance.

At 12- and 18-months follow-up
Patient reported dyspnea score
大体时间:At 12- and 18-months follow-up

Prevalance and impact of dyspnea on patient's daily activities classified by the Medical Research Council Dyspnea Scale. There are 5 grades (0 to 4). The higher the grade, the greater the impact.

At 12- and 18-months follow-up
Cost effectiveness analysis between the two treatment groups
大体时间:At 18 months follow-up

Compare healthcare costs and health outcomes of the two treatment arms. Healthcare costs are determined by extracting healthcare utilization data from electronic health records and multiplying these resource-use frequencies by their corresponding standard unit costs in euros. Health outcomes will be evaluated by assessing patient-reported quality of life through the validated questionnaires EuroQol 5 Dimensions (EQ5D). Quality adjusted life years (QALYs) will be derived from the EQ5D outcomes. Costs per QALY will be compared per treatment arm to compare cost-effectiveness.

At 18 months follow-up
Patient reported quality of life
大体时间:At 30 days, 12- and 18-months follow-up

Measured by the validated questionnaire EuroQol 5 Dimensions (EQ5D). The EQ5D evaluates a patient's health accross five core dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) giving it a score of 1 (no problems) to 5 (extreme problems).

At 30 days, 12- and 18-months follow-up

其他结果措施

结果测量
措施说明
大体时间
Intention to treat analysis without 30-day adverse event exclusion
大体时间:At 12- and 18-months follow-up

The primary and secondary endpoints will be evaluated in all patients who were initially included at time of ACS diagnosis based on their randomized treatment, i.e., independent of adverse events in the first 30 days after ACS diagnosis and irrespective of received treatment.

At 12- and 18-months follow-up
Outcome differences in bleeding events
大体时间:At 18-months follow-up

To compare bleeding events (%) in both treatment arms.

At 18-months follow-up
Relation between patients ethnic background (self-reported) and clinical presentation
大体时间:At 18-months follow-up

Does self-defined ethnic background impact the incidence of clinical presentation (STEMI/NSTEMI/unstable angina). For example, is there an association between non-Western European ethnic background and the type of clinical presentation (STEMI/NSTEMI/unstable angina).

At 18-months follow-up
Relation between patients highest obtained education level and clinical outcome
大体时间:At 18-months follow-up

Is there a negative correlation between the highest obtained educational level and the incidence of the primary and secondary endpoints (%)

At 18-months follow-up
Correlation between Non-enrollers and enrollers
大体时间:18 months

Clinical outcome (based on primary and secondary endpoints) of patients who were not enrolled vs patients who were enrolled in the study based on data from medical records

18 months
Outcome differences diabetes mellitus
大体时间:At 18 months follow-up

Differences in primary and secondary endpoints (%) of diabetic vs non-diabetic participants.

At 18 months follow-up
Outcome differences gender
大体时间:At 18 months follow-up

Differences in primary and secondary endpoints (%) of male vs female participants.

At 18 months follow-up
Outcome differences elderly
大体时间:At 18 months follow-up

Differences in primary and secondary endpoints (%) of elderly (>= 75 years) vs non-elderly participants.

At 18 months follow-up
Outcome differences invasive acute coronary syndrome treatment
大体时间:At 18 months follow-up

Differences in primary and secondary endpoints (%) of participants treated with percutaneous coronary intervention vs non-invasively-treated.

At 18 months follow-up
Outcome differences multivessel disease
大体时间:At 18 months follow-up

Differences in primary and secondary endpoints (%) of participants treated with multivessel percutaneous intervention vs non treated with mutlivessel percutaneous intervention.

At 18 months follow-up
Outcome differences acute coronary syndrome type
大体时间:At 18 months follow-up

Differences in primary and secondary endpoints (%) of participants with acute myocardial infarction vs unstable angina.

At 18 months follow-up
Relation between patients ethnic background (self-reported) and dual antiplatelet use
大体时间:At 18 months

Does self-reported ethnic background impact the incidence of dual antiplatelet use (therapy adherence). For example, does non-Western European ethnic background have an association with higher therapy adherence? This will be measured by self-reported adherence and pharmacist's records of dual antiplatelet therapy pick up.

At 18 months
Relation between patients ethnic background (self-reported) and clinical outcome
大体时间:At 18 months

Does ethnic background impact the incidence of the clinical outcome (primary and secondary endpoints). For example, is there an association between non-Western European ethnic background and lower rates of the primary or secondary endpoints.

At 18 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Clemens von Birgelen, MD, Prof. Dr.、Medisch Spectrum Twente
  • 研究主任:Eline Ploumen, MD, PhD、Medisch Spectrum Twente

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月15日

初级完成 (估计的)

2029年11月15日

研究完成 (估计的)

2030年3月1日

研究注册日期

首次提交

2026年8月26日

首先提交符合 QC 标准的

2026年11月9日

首次发布 (实际的)

2026年11月16日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅